Westin Explains the Need for Novel Therapies in the Endometrial Cancer Space
Shannon Westin, MD, MPH, FACOG, a gynecologic oncologist at The University of Texas MD Anderson Cancer Center, discusses the use of durvalumab with or without olaparib for the treatment of endometrial cancers.
Future Treatment of Ovarian Cancer
The future of ovarian cancer treatment is discussed through a summary of current treatment options, future directions, and a review the unmet needs facing patients and physicians today.
Treatment Considerations With Niraparib
Shannon Westin, MD, reviews essential treatment considerations for physicians when subscribing niraparib.
PARP Inhibitors in Ovarian Cancer Treatment
The utilization and effectiveness of using PARP inhibitors in treating ovarian cancer is considered.
Niraparib in the PRIMA Trial
Shannon Westin, MD, discusses niraparib and its relation to the design, efficacy, and practical implications of the PRIMA trial.
Frontline Treatment Options in Ovarian Cancer
Systemic frontline therapy options are explored through the lens of treating ovarian cancer.
Molecular Testing in Ovarian Cancer
Shannon Westin, MD, analyzes the role of molecular testing in newly diagnosed ovarian cancer.
Prognosis of Patients With Ovarian Cancer
Shannon Westin, MD, discusses the prognosis of the case patient and the general prognosis and treatment options for ovarian cancer patients overall.
Analysis of Patient Diagnosis and Treatment
Shannon Westin, MD, introduces the case patient and highlights the diagnosis and treatment path to combat stage IV ovarian cancer.
Expert Perspectives on Treating Recurrent Ovarian Cancer
Shannon Westin, MD, analyzes the diagnosis and treatment of a 68-year-old woman with recurrent ovarian cancer.
2 Clarke Drive Cranbury, NJ 08512